Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS

Bioanalysis

Volumn 2, Issue 4, 2010, Pages 733-743

  Fung, Eliza N ^a   Zheng, Naiyu ^a   Arnold, Mark E ^a   Zeng, Jianing ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BENZYLSULFONYL FLUORIDE; BIS(4 NITROPHENYL) PHOSPHATE; DICHLORVOS; DIISOPROPYL FLUOROPHOSPHATASE; ESTER; ESTERASE INHIBITOR; FLUORIDE SODIUM; PARAOXON; PHYSOSTIGMINE; PRODRUG; THENOYLTRIFLUOROACETONE; ENZYME INHIBITOR; ESTERASE;

ARTICLE; BIOASSAY; BLOOD PH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG STABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROCESS OPTIMIZATION; RAT; ROOM TEMPERATURE; ANIMAL; BLOOD; CHEMISTRY; DRUG ANTAGONISM; METHODOLOGY; SPECIES DIFFERENCE; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; ENZYME INHIBITORS; ESTERASES; ESTERS; HUMANS; PRODRUGS; RATS; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 78650643244     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.30     Document Type: Article

References (20)

1. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: design and clinical applications. Nat. Rev. 7, 255-270 (2008). (Pubitemid 351324639)
2. Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 4, 461-485 (2003). (Pubitemid 37540382)
3. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 59, 677-694 (2007). (Pubitemid 47285410)
4. Grossman SJ. Safety assessment of prodrugs. In: Prodrugs: Challenges and Rewards (Part 2). Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW (Eds). AAPS/Springer, NY, USA, 411-424 (2007).
5. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95, 1177-1195 (2006). (Pubitemid 43874435)
6. Zeng J, Onthank D, Crane P et al. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry - evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug J. Chromtogr. B 852, 77-84 (2007). (Pubitemid 46830102)
7. Yang JZ, Chen W, Borchardt RT. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly- Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J. Pharmacol. Exp. Ther. 303, 840-848 (2002). (Pubitemid 35231261)
8. Wiltshire H, Wiltshire B, Citron A et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its prodrug, oseltamivir, in human and animal plasma and urine. J. Chromatogr. B 745, 373-388 (2000). (Pubitemid 30665562)
9. Lindegardh N, Davies GR, Hien TT et al. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob. Agents Chemother. 50, 3197-3199 (2006). (Pubitemid 44396439)
10. Minagawa T, Kohno Y, Suwa T et al. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem. Pharmacol. 49, 1361-1365 (1995).
11. Liederer BM, Borchardt RT. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J. Pharm. Sci. 94, 2198-2206 (2005). (Pubitemid 41665281)
12. Yamaori S, Fujiyama N, Kushihara M et al. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab. Pharmacokinet. 21, 147-155 (2006).
13. Kudo S, Umehara K, Hosokawa M et al. Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation. J. Pharmacol. Exp. Ther. 294, 80-88 (2000).
14. Zhang J, Fariss MW. Thenoyltrifluoroacetone, a potent inhibitor of carboxylesterase activity. Biochem. Pharmacol. 63, 751-754 (2002). (Pubitemid 34457707)
15. Wang JJ, Cheng WX, Ding W et al. The effect of the insecticide dichlorvos on esterase activity extracted from the psocids, Liposcelis bostrychophila and L. entomophila. J. Insect Sci. 4, 1-5 (2004). (Pubitemid 40240172)
16. Yoshigae Y, Imai T, Taketani M et al. Characterization of esterase involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma. Chirality 11, 10-13 (1999). (Pubitemid 29016325)
17. Kelly SJ, Dardinger DE, Butler LG. Hydrolysis of phosphonate esters catalyzed by 5′-nucleotide phosphodiesterase. Biochemistry 14, 4983-4988 (1975).
18. Tsujikawa K, Kuwayama K, Miyaguchi H et al. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 39, 391-398 (2009).
19. Findlay RD, Taeusch HW, David-Cu R et al. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatic Res. 37, 26-30 (1995).
20. Lindegardh N, Davies GR, Hien TT et al. Importance of collection tube during clinical studies of oseltamivir. Antimicrob. Agents Chemother. 51, 1835-1836 (2007). (Pubitemid 46744167)